PDCD1 and neoplasm: In early studies, immune checkpoint inhibitors (ICIs) (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1) were investigated in combination with ICPs, and ICPs could be used in the treatment of tumor immune escape through immune checkpoint blockade(ICB) therapy (15, 16).